Welcome to our dedicated page for Psybio Therapeau news (Ticker: PSYBF), a resource for investors and traders seeking the latest updates and insights on Psybio Therapeau stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Psybio Therapeau's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Psybio Therapeau's position in the market.
Summary not available.
PsyBio Therapeutics Corp. (TSXV: PSYB, OTCQB: PSYBF) will be presenting at the KCSA Psychedelics Investor Conference on October 14th at 10:30 a.m. ET. The conference aims to showcase innovative biotechnology focused on developing psycho-targeted therapeutics for mental health improvement. Interested participants can register here. PsyBio's expertise lies in drug discovery through synthetic biology and metabolic engineering, utilizing psychoactive compounds derived from hallucinogenic mushrooms to develop novel therapies.
PsyBio Therapeutics Corp. (OTCQB: PSYBF) announced the commencement of trading of its subordinate voting shares on the OTCQB Venture Market on July 14, 2021. This listing aims to increase visibility among U.S. investors and enhance liquidity for shareholders. The company is also applying for DTC eligibility, which will facilitate electronic settlement of stock transfers, making it easier for investors. PsyBio continues to trade on the TSX Venture Exchange as PSYB and on the Frankfurt Stock Exchange as PSYB.F.